{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T14:26:10Z","timestamp":1783607170057,"version":"3.55.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,5,11]],"date-time":"2024-05-11T00:00:00Z","timestamp":1715385600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,5,11]],"date-time":"2024-05-11T00:00:00Z","timestamp":1715385600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"DOI":"10.1007\/s00345-024-04992-5","type":"journal-article","created":{"date-parts":[[2024,5,11]],"date-time":"2024-05-11T20:15:56Z","timestamp":1715458556000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Induction and maintenance of sequential intravesical gemcitabine\/docetaxel for intermediate and high-risk non-muscle invasive bladder cancer with different dosage protocols"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7946-7145","authenticated-orcid":false,"given":"Reuben","family":"Ben-David","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeraja","family":"Tillu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parissa","family":"Alerasool","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Bieber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Ranti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Tolani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Eisenhauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rainjade","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etienne","family":"Lavall\u00e9e","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikhil","family":"Waingankar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyrollis","family":"Attalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Wiklund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reza","family":"Mehrazin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher B.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P.","family":"Sfakianos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,11]]},"reference":[{"key":"4992_CR1","unstructured":"Bladder Cancer\u2014Cancer Stat Facts [Internet]. [cited 2023 Aug 23]. Available from: https:\/\/seer.cancer.gov\/statfacts\/html\/urinb.html"},{"key":"4992_CR2","doi-asserted-by":"publisher","first-page":"1044830","DOI":"10.3389\/fonc.2022.1044830","volume":"12","author":"S Deng","year":"2022","unstructured":"Deng S, Meng F, Wang L, Yang Z, Xuan L, Xuan Z et al (2022) Global research trends in non-muscle invasive bladder cancer: Bibliometric and visualized analysis. Front Oncol 12:1044830","journal-title":"Front Oncol"},{"issue":"2","key":"4992_CR3","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1159\/000499257","volume":"14","author":"JCM Wan","year":"2020","unstructured":"Wan JCM (2020) Survival outcomes of early versus deferred cystectomy for non-muscle-invasive bladder cancer: a systematic review. Curr Urol 14(2):66\u201373. https:\/\/doi.org\/10.1159\/000499257","journal-title":"Curr Urol"},{"key":"4992_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2016.06.049","author":"SS Chang","year":"2016","unstructured":"Chang SS, Boorjian SA, Chou R, Clark PE, Daneshmand S, Konety BR et al (2016) Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline. J Urol. https:\/\/doi.org\/10.1016\/j.juro.2016.06.049","journal-title":"J Urol."},{"key":"4992_CR5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JGO.19.11000","volume":"5","author":"ML Wroclawski","year":"2019","unstructured":"Wroclawski ML, Schutz FA, Cha JD, Soares A (2019) Alternative therapies to bacillus calmette-gu\u00e9rin shortage for nonmuscle invasive bladder cancer in brazil and other underdeveloped countries: management considerations. J Glob Oncol 5:1\u20139","journal-title":"J Glob Oncol"},{"issue":"5","key":"4992_CR6","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1007\/s00345-021-03908-x","volume":"40","author":"A Balasubramanian","year":"2022","unstructured":"Balasubramanian A, Gunjur A, Weickhardt A, Papa N, Bolton D, Lawrentschuk N et al (2022) Adjuvant therapies for non-muscle-invasive bladder cancer: advances during BCG shortage. World J Urol 40(5):1111\u20131124","journal-title":"World J Urol"},{"issue":"5","key":"4992_CR7","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/j.eururo.2020.04.066","volume":"78","author":"MO Grimm","year":"2020","unstructured":"Grimm MO, van der Heijden AG, Colombel M, Muilwijk T, Mart\u00ednez-Pi\u00f1eiro L, Babjuk MM et al (2020) Treatment of high-grade non-muscle-invasive bladder carcinoma by standard number and dose of BCG instillations versus reduced number and standard dose of BCG instillations: results of the european association of urology research foundation randomised pha. Eur Urol 78(5):690\u2013698","journal-title":"Eur Urol"},{"issue":"1","key":"4992_CR8","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.eururo.2021.12.005","volume":"82","author":"M Roumigui\u00e9","year":"2022","unstructured":"Roumigui\u00e9 M, Kamat AM, Bivalacqua TJ, Lerner SP, Kassouf W, B\u00f6hle A et al (2022) international bladder cancer group consensus statement on clinical trial design for patients with bacillus calmette-gu\u00e9rin-exposed high-risk non-muscle-invasive bladder cancer. Eur Urol 82(1):34\u201346","journal-title":"Eur Urol"},{"issue":"1","key":"4992_CR9","first-page":"65","volume":"1","author":"RL Steinberg","year":"2015","unstructured":"Steinberg RL, Thomas LJ, O\u2019Donnell MA, Nepple KG (2015) Sequential intravesical gemcitabine and docetaxel for the salvage treatment of non-muscle invasive bladder cancer. Bl Cancer (Amsterdam, Netherlands) 1(1):65\u201372","journal-title":"Bl Cancer (Amsterdam, Netherlands)"},{"key":"4992_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2023.06.017","author":"IM McElree","year":"2023","unstructured":"McElree IM, Orzel J, Stubbee R, Steinberg RL, Mott SL, O\u2019Donnell MA et al (2023) Sequential intravesical gemcitabine and docetaxel for treatment-na\u00efve and previously treated intermediate-risk nonmuscle invasive bladder cancer. Urol Oncol. https:\/\/doi.org\/10.1016\/j.urolonc.2023.06.017","journal-title":"Urol Oncol."},{"issue":"3","key":"4992_CR11","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1097\/JU.0000000000002740","volume":"208","author":"IM McElree","year":"2022","unstructured":"McElree IM, Steinberg RL, Martin AC, Richards J, Mott SL, Gellhaus PT et al (2022) Sequential intravesical gemcitabine and docetaxel for bacillus calmette-gu\u00e9rin-na\u00efve high-risk nonmuscle-invasive bladder cancer. J Urol 208(3):589\u2013599","journal-title":"J Urol"},{"issue":"4","key":"4992_CR12","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1200\/JCO.2008.20.8199","volume":"28","author":"R Addeo","year":"2010","unstructured":"Addeo R, Caraglia M, Bellini S, Abbruzzese A, Vincenzi B, Montella L et al (2010) Randomized phase III trial on gemcitabine versus mytomicin in recurrent superficial bladder cancer: evaluation of efficacy and tolerance. J Clin Oncol Off J Am Soc Clin Oncol 28(4):543\u2013548","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"8","key":"4992_CR13","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1002\/cncr.24914","volume":"116","author":"G Di Lorenzo","year":"2010","unstructured":"Di Lorenzo G, Perdon\u00e0 S, Damiano R, Faiella A, Cantiello F, Pignata S et al (2010) Gemcitabine versus bacille Calmette-Gu\u00e9rin after initial bacille Calmette-Gu\u00e9rin failure in non-muscle-invasive bladder cancer: a multicenter prospective randomized trial. Cancer 116(8):1893\u20131900","journal-title":"Cancer"},{"key":"4992_CR14","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.euros.2021.01.009","volume":"26","author":"ME Rezaee","year":"2021","unstructured":"Rezaee ME, Ismail AAO, Okorie CL, Seigne JD, Lynch KE, Schroeck FR (2021) Partial versus complete bacillus calmette-gu\u00e9rin intravesical therapy and bladder cancer outcomes in high-risk non-muscle-invasive bladder cancer: is NIMBUS the full story? Eur Urol open Sci 26:35\u201343","journal-title":"Eur Urol open Sci"},{"key":"4992_CR15","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1002\/tre.783","volume":"12","author":"N Mayor","year":"2021","unstructured":"Mayor N, Fankhauser C, Sangar V, Mostafid H (2021) Management of NMIBC during BCG shortage and COVID-19. Trends Urol Men\u2019s Health. 12:7\u201311","journal-title":"Trends Urol Men\u2019s Health."},{"issue":"2","key":"4992_CR16","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1097\/SLA.0b013e3181b13ca2","volume":"250","author":"PA Clavien","year":"2009","unstructured":"Clavien PA, Barkun J, de Oliveira ML, Vauthey JN, Dindo D, Schulick RD et al (2009) The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg 250(2):187\u2013196","journal-title":"Ann Surg"},{"issue":"2","key":"4992_CR17","first-page":"113","volume":"18","author":"RJ Sylvester","year":"2011","unstructured":"Sylvester RJ (2011) Bacillus Calmette-Gu\u00e9rin treatment of non-muscle invasive bladder cancer. Int J Urol Off J Japanese Urol Assoc 18(2):113\u2013120","journal-title":"Int J Urol Off J Japanese Urol Assoc"},{"issue":"2","key":"4992_CR18","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.juro.2014.02.2573","volume":"192","author":"AM Kamat","year":"2014","unstructured":"Kamat AM, Witjes JA, Brausi M, Soloway M, Lamm D, Persad R et al (2014) Defining and treating the spectrum of intermediate risk nonmuscle invasive bladder cancer. J Urol 192(2):305\u2013315","journal-title":"J Urol"},{"key":"4992_CR19","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000002633.14","author":"K Yim","year":"2023","unstructured":"Yim K, Melnick K, Mott SL, Carvalho FLF, Zafar A, Clinton TN et al (2023) Sequential intravesical gemcitabine\/docetaxel provides a durable remission in recurrent high-risk NMIBC following BCG therapy. Urol Oncol. https:\/\/doi.org\/10.1097\/JU.0000000000002633.14","journal-title":"Urol Oncol."},{"issue":"1","key":"4992_CR20","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1186\/s12894-020-00766-4","volume":"20","author":"D Koguchi","year":"2020","unstructured":"Koguchi D, Matsumoto K, Hirayama T, Moroo S, Kobayashi M, Katsumata H et al (2020) Impact of maintenance therapy using a half dose of the bacillus Calmette-Gu\u00e9rin Tokyo strain on recurrence of intermediate and high-risk nonmuscle invasive bladder cancer: a retrospective single-center study. BMC Urol 20(1):194","journal-title":"BMC Urol"},{"issue":"5","key":"4992_CR21","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1016\/j.eururo.2009.12.024","volume":"57","author":"RJ Sylvester","year":"2010","unstructured":"Sylvester RJ, Brausi MA, Kirkels WJ, Hoeltl W, Calais Da Silva F, Powell PH et al (2010) Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Gu\u00e9rin, and bacillus Calmette-Gu\u00e9rin plus isoniazid in patients with intermediate- and high-risk. Eur Urol. 57(5):766\u201373","journal-title":"Eur Urol."},{"issue":"4","key":"4992_CR22","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1016\/S0022-5347(05)67707-5","volume":"163","author":"DL Lamm","year":"2000","unstructured":"Lamm DL, Blumenstein BA, Crissman JD, Montie JE, Gottesman JE, Lowe BA et al (2000) Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol 163(4):1124\u20131129","journal-title":"J Urol"},{"issue":"2","key":"4992_CR23","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.0849","volume":"6","author":"IM McElree","year":"2023","unstructured":"McElree IM, Steinberg RL, Mott SL, O\u2019Donnell MA, Packiam VT (2023) Comparison of Sequential Intravesical Gemcitabine and Docetaxel vs Bacillus Calmette-Gu\u00e9rin for the treatment of patients with high-risk non-muscle-invasive bladder cancer. JAMA Netw open 6(2):e230849","journal-title":"JAMA Netw open"},{"issue":"4","key":"4992_CR24","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1111\/j.1464-410X.2011.10880.x","volume":"109","author":"MD Shelley","year":"2012","unstructured":"Shelley MD, Jones G, Cleves A, Wilt TJ, Mason MD, Kynaston HG (2012) Intravesical gemcitabine therapy for non-muscle invasive bladder cancer (NMIBC): a systematic review. BJU Int 109(4):496\u2013505","journal-title":"BJU Int"},{"issue":"3","key":"4992_CR25","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.eururo.2004.05.001","volume":"46","author":"P Gontero","year":"2004","unstructured":"Gontero P, Casetta G, Maso G, Sogni F, Pretti G, Zitella A et al (2004) Phase II study to investigate the ablative efficacy of intravesical administration of gemcitabine in intermediate-risk superficial bladder cancer (SBC). Eur Urol 46(3):339\u2013343","journal-title":"Eur Urol"},{"issue":"4","key":"4992_CR26","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/j.urology.2005.04.062","volume":"66","author":"R Bartoletti","year":"2005","unstructured":"Bartoletti R, Cai T, Gacci M, Giubilei G, Viggiani F, Santelli G et al (2005) Intravesical gemcitabine therapy for superficial transitional cell carcinoma: results of a Phase II prospective multicenter study. Urology 66(4):726\u2013731","journal-title":"Urology"},{"issue":"11","key":"4992_CR27","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1111\/j.1464-410X.2010.09496.x","volume":"106","author":"P Gontero","year":"2010","unstructured":"Gontero P, Cattel L, Paone TC, Milla P, Berta G, Fiorito C et al (2010) Pharmacokinetic study to optimize the intravesical administration of gemcitabine. BJU Int 106(11):1652\u20131656","journal-title":"BJU Int"},{"issue":"5","key":"4992_CR28","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1097\/JU.0000000000000688","volume":"203","author":"RL Steinberg","year":"2020","unstructured":"Steinberg RL, Thomas LJ, Brooks N, Mott SL, Vitale A, Crump T et al (2020) Multi-institution evaluation of sequential gemcitabine and docetaxel as rescue therapy for nonmuscle invasive bladder cancer. J Urol 203(5):902\u2013909","journal-title":"J Urol"},{"key":"4992_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2023.06.011","author":"WS Tan","year":"2023","unstructured":"Tan WS, McElree IM, Davaro F, Steinberg RL, Bree K, Navai N et al (2023) Sequential intravesical gemcitabine and docetaxel is an alternative to Bacillus Calmette-Gu\u00e9rin for the treatment of intermediate-risk non-muscle-invasive bladder cancer. Eur Urol Oncol. https:\/\/doi.org\/10.1016\/j.euo.2023.06.011","journal-title":"Eur Urol Oncol."},{"issue":"2","key":"4992_CR30","doi-asserted-by":"publisher","first-page":"40.e17","DOI":"10.1016\/j.urolonc.2019.07.022","volume":"38","author":"MJ Daniels","year":"2020","unstructured":"Daniels MJ, Barry E, Milbar N, Schoenberg M, Bivalacqua TJ, Sankin A et al (2020) An evaluation of monthly maintenance therapy among patients receiving intravesical combination gemcitabine\/docetaxel for nonmuscle-invasive bladder cancer. Urol Oncol 38(2):40.e17-40.e24","journal-title":"Urol Oncol"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-024-04992-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-024-04992-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-024-04992-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T21:30:40Z","timestamp":1735853440000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00345-024-04992-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,11]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["4992"],"URL":"https:\/\/doi.org\/10.1007\/s00345-024-04992-5","relation":{},"ISSN":["1433-8726"],"issn-type":[{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,11]]},"assertion":[{"value":"25 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study protocol was approved by the local Ethics Committee (#23\u201301201), informed consent was waived.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"315"}}